Jarrett R J, Keen H, Fuller J H, McCartney M
Br Med J. 1977 Oct 1;2(6091):861-5. doi: 10.1136/bmj.2.6091.861.
A five-year therapeutic trial of carbohydrate restriction with or without phenformin (50 mg/day) was performed in men with borderline diabetes. The aim of treatment was to diminish the enhanced risk of cardiovascular disease and deterioration of glucose tolerance. Cardiovascular morbidity and mortality were not significantly affected by any form of treatment, alone or in combination. The predominant risk factor for cardiovascular morbidity and mortality and for overall mortality was the initial blood pressure level. The baseline plasma cholesterol concentration significantly predicted the onset of intermittent claudication. One implication of the results is that hypotensive treatment, supplemented when necessary with hypolipidaemic treatment, may be more effective in preventing the progression of arterial disease in people with mild to moderate glucose intolerance than conventional antidiabetic therapy.
对患有边缘性糖尿病的男性进行了一项为期五年的治疗试验，该试验采用了限制碳水化合物饮食，部分患者同时服用苯乙双胍（50毫克/天）。治疗的目的是降低心血管疾病风险增加以及糖耐量恶化的情况。单独或联合使用任何一种治疗方式，对心血管发病率和死亡率均无显著影响。心血管发病率、死亡率以及总体死亡率的主要风险因素是初始血压水平。基线血浆胆固醇浓度可显著预测间歇性跛行的发生。研究结果的一个启示是，对于轻度至中度糖耐量异常的人群，降压治疗（必要时辅以降脂治疗）可能比传统抗糖尿病治疗在预防动脉疾病进展方面更有效。
